Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.
News|Videos|July 1, 2024
Learn about the MyFreeStyle program
Advertisement
Advertisement
Related to this article
Data assessing Novo Nordisk’s investigational diabetes and obesity medication were presented at The Menopause Society's 2026 Annual Meeting.
Eli Lilly released phase 2b trial results comparing the investigational eloralintide-tirzepatide combo with tirzepatide 15 mg alone in patients with T2D and obesity.
Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
Advertisement
Advertisement
Trending on Drug Topics
1
American Pharmacists Month: Technology’s Role in Expanding Pharmacist Scope
2
HHS Lets Pharmacies Compound Peptides as FDA Writes Official Rule
3
PBMs Must Now Disclose Fees to Employer Plans Under Final DOL Rule
4
American Pharmacists Month: PBM Reform, Provider Status Key in Stopping Pharmacy Deserts
5